Vaxart, Inc., released clinical results on Tuesday that showed its H1N1 tablet vaccine is just as reliable as currently licensed flu vaccines.
“Our tablet flu vaccine generated broad immune responses in more than 90 percent of recipients,” Vaxart CEO Wouter Latour said. “We are seeing a safety-immunogenicity profile that could compete with that of any of the currently marketed vaccines even without taking into account the convenience and logistical advantages of our room-temperature stable and user-friendly tablet. In addition our tablet vaccine could significantly increase vaccination rates currently at about 45 percent of the U.S. population.”
Common Management Taxonomy: